Pharma News

Pharma major Lupin Limited (Lupin) announced a contribution of INR 21 crores for relief efforts directed towards mitigating the COVID-19 crisis. Lupin’s Global Giving Program comprises of three separate contributions made by its employees, the Company and the promoter family.

BioNTech SE and Pfizer Inc disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine program, previously announced on March 17, 2020.

The U.S. Food and Drug Administration issued an emergency use authorization for a blood purification system to treat patients 18 years of age or older with confirmed Coronavirus Disease 2019 (COVID-19) admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure.

Sun Pharmaceuticals shares are floating higher to Rs. 452.50 on BSE on Friday and expected to improve company's outlook. It was reached 52 week high at Rs. 479.90 on 10th April, 2020.

There will not be any shortage of hydroxychloroquine in the country either today or in the future. Community support plays an important role in helping to identify cases early which in turn is key to containing spread and mortality due to COVID-19. States have started providing assistance to building and construction sector workers, as per the component under Rs. 1.7 lakh crore Pradhan Mantri Garib Kalyan Yojana package : Union Home Affairs Ministry.

CSIR-Central Electrochemical Research Institute (CECRI), a premier research establishment under the aegis of Council of Scientific and Industrial Research (CSIR), New Delhi, focussing on a gamut of problems covering all facets of electrochemical science and technology: viz., Corrosion Science and Engineering, Electrochemical Power Sources, Electrochemical Materials Science, Electro-organic and Electro-inorganic Chemicals, Electrodics and Electrocatalysis, Electro-metallurgy, Electro Plating and Metal Finishing Technology. CSIRCECRI's activities are directed towards the development of new and improved products and process as well as innovations in electrochemical science and technology. CSIR-CECRI runs several projects in collaboration with laboratories and private companies within and outside India.

Three classes of facilities to be set up for various categories of COVID-19 patients: Health Ministry’s guidance document for managing COVID-19, Government strategy for cluster containment and for managing outbreaks yielding positive results in some areas : Union Health Ministry

The first published data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) study supports the hypothesis that higher levels of the amyloid protein in the brain represent an early stage of Alzheimer’s disease. Results of an analysis of participant screening data for the study, published April 6 in JAMA Neurology, also show that amyloid burden in clinically normal older adults is associated with a family history of disease, lower cognitive test scores, and reports of declines in daily cognitive function. Major funding was provided by the National Institute on Aging (NIA), part of the National Institutes of Health; all data is now freely available to the broader research community.

The continued availability of medicines, in particular those used for patients with COVID-19, is of critical concern for EMA and its partners in the European medicines regulatory network in light of the medical emergency presented by the pandemic.

In a dedicated COVID-19 workshop, organised by the European Medicines Agency (EMA) under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), international regulators discussed how data generated during clinical practice could complement evidence from clinical trials with potential therapeutics or vaccines against COVID-19. Participants from more than 25 countries, representing 28 medicines regulatory authorities globally and experts from the World Health Organization and the European Commission acknowledged the importance of observational studies of real world data for increasing the effectiveness and efficiency of regulatory processes and decision-making in the development, authorisation and monitoring of medicines and vaccines to prevent and treat COVID-19 and to address knowledge gaps that cannot be addressed by clinical trials.